Prevention and Treatment of Acute Stroke in the Nonagenarians and Beyond

Medical and Ethical Issues

Tiberiu A Pana, Jesus A Perdomo-Lampignano, Phyo K Myint (Corresponding Author)

Research output: Contribution to journalArticle

Abstract

Purpose of review
As one of the fastest growing portions of the population, nonagenarians will constitute a significant percentage of the stroke patient population in the near future. Nonagenarians are nevertheless not specifically targeted by most clinical guidelines. In this review, we aimed to summarise the available evidence guiding stroke prevention and treatment in this age group.

Recent findings
Several recent observational studies have shown that the benefits of anticoagulation for the oldest old patients with atrial fibrillation may outweigh the bleeding risk. A sub-analysis of the IST-3 trial has shown for the first time that thrombolysis treatment in acute ischaemic stroke may be beneficial and safe even in octogenarian patients and older. Several recent observational studies have assessed thrombolysis in nonagenarians. The latest of these has shown better disability outcomes without increased rates of symptomatic intracerebral haemorrhage with thrombolysis.

Summary
Nonagenarian stroke patients may benefit from similar preventative and therapeutic strategies as their younger counterparts. A few important exceptions include primary prevention using aspirin or statins. Patient selection is nevertheless essential given the increased adverse event rates. Patient preference should play a key role in the decision-making process. Clinical trials including more nonagenarian patients are required to yield more robust evidence.
Original languageEnglish
Article number27
Number of pages18
JournalCurrent Treatment Options in Neurology
Volume21
Issue number6
Early online date8 May 2019
DOIs
Publication statusPublished - 1 Jun 2019

Fingerprint

Ethics
Stroke
Observational Studies
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Patient Preference
Cerebral Hemorrhage
Primary Prevention
Atrial Fibrillation
Patient Selection
Population
Aspirin
Decision Making
Age Groups
Clinical Trials
Guidelines
Hemorrhage

Keywords

  • stroke
  • cerebrovascular disease
  • Nonagenarian
  • oldest old
  • prevention
  • management
  • Prevention
  • Stroke
  • Oldest old
  • Management
  • Cerebrovascular disease
  • LEFT ATRIAL APPENDAGE
  • TISSUE-PLASMINOGEN ACTIVATOR
  • CAROTID-ENDARTERECTOMY
  • INDIVIDUAL PATIENT DATA
  • HEALTH-CARE PROFESSIONALS
  • ACUTE ISCHEMIC-STROKE
  • DIRECT ORAL ANTICOAGULANTS
  • CHRONIC KIDNEY-DISEASE
  • ELDERLY-PATIENTS
  • 80 YEARS OLD

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Prevention and Treatment of Acute Stroke in the Nonagenarians and Beyond : Medical and Ethical Issues. / Pana, Tiberiu A ; Perdomo-Lampignano, Jesus A ; Myint, Phyo K (Corresponding Author).

In: Current Treatment Options in Neurology, Vol. 21, No. 6, 27, 01.06.2019.

Research output: Contribution to journalArticle

@article{14c2bd7cba264f11a8ea608c4ee7a17b,
title = "Prevention and Treatment of Acute Stroke in the Nonagenarians and Beyond: Medical and Ethical Issues",
abstract = "Purpose of reviewAs one of the fastest growing portions of the population, nonagenarians will constitute a significant percentage of the stroke patient population in the near future. Nonagenarians are nevertheless not specifically targeted by most clinical guidelines. In this review, we aimed to summarise the available evidence guiding stroke prevention and treatment in this age group.Recent findingsSeveral recent observational studies have shown that the benefits of anticoagulation for the oldest old patients with atrial fibrillation may outweigh the bleeding risk. A sub-analysis of the IST-3 trial has shown for the first time that thrombolysis treatment in acute ischaemic stroke may be beneficial and safe even in octogenarian patients and older. Several recent observational studies have assessed thrombolysis in nonagenarians. The latest of these has shown better disability outcomes without increased rates of symptomatic intracerebral haemorrhage with thrombolysis.SummaryNonagenarian stroke patients may benefit from similar preventative and therapeutic strategies as their younger counterparts. A few important exceptions include primary prevention using aspirin or statins. Patient selection is nevertheless essential given the increased adverse event rates. Patient preference should play a key role in the decision-making process. Clinical trials including more nonagenarian patients are required to yield more robust evidence.",
keywords = "stroke, cerebrovascular disease, Nonagenarian, oldest old, prevention, management, Prevention, Stroke, Oldest old, Management, Cerebrovascular disease, LEFT ATRIAL APPENDAGE, TISSUE-PLASMINOGEN ACTIVATOR, CAROTID-ENDARTERECTOMY, INDIVIDUAL PATIENT DATA, HEALTH-CARE PROFESSIONALS, ACUTE ISCHEMIC-STROKE, DIRECT ORAL ANTICOAGULANTS, CHRONIC KIDNEY-DISEASE, ELDERLY-PATIENTS, 80 YEARS OLD",
author = "Pana, {Tiberiu A} and Perdomo-Lampignano, {Jesus A} and Myint, {Phyo K}",
year = "2019",
month = "6",
day = "1",
doi = "10.1007/s11940-019-0567-0",
language = "English",
volume = "21",
journal = "Current Treatment Options in Neurology",
issn = "1534-3138",
publisher = "Springer",
number = "6",

}

TY - JOUR

T1 - Prevention and Treatment of Acute Stroke in the Nonagenarians and Beyond

T2 - Medical and Ethical Issues

AU - Pana, Tiberiu A

AU - Perdomo-Lampignano, Jesus A

AU - Myint, Phyo K

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Purpose of reviewAs one of the fastest growing portions of the population, nonagenarians will constitute a significant percentage of the stroke patient population in the near future. Nonagenarians are nevertheless not specifically targeted by most clinical guidelines. In this review, we aimed to summarise the available evidence guiding stroke prevention and treatment in this age group.Recent findingsSeveral recent observational studies have shown that the benefits of anticoagulation for the oldest old patients with atrial fibrillation may outweigh the bleeding risk. A sub-analysis of the IST-3 trial has shown for the first time that thrombolysis treatment in acute ischaemic stroke may be beneficial and safe even in octogenarian patients and older. Several recent observational studies have assessed thrombolysis in nonagenarians. The latest of these has shown better disability outcomes without increased rates of symptomatic intracerebral haemorrhage with thrombolysis.SummaryNonagenarian stroke patients may benefit from similar preventative and therapeutic strategies as their younger counterparts. A few important exceptions include primary prevention using aspirin or statins. Patient selection is nevertheless essential given the increased adverse event rates. Patient preference should play a key role in the decision-making process. Clinical trials including more nonagenarian patients are required to yield more robust evidence.

AB - Purpose of reviewAs one of the fastest growing portions of the population, nonagenarians will constitute a significant percentage of the stroke patient population in the near future. Nonagenarians are nevertheless not specifically targeted by most clinical guidelines. In this review, we aimed to summarise the available evidence guiding stroke prevention and treatment in this age group.Recent findingsSeveral recent observational studies have shown that the benefits of anticoagulation for the oldest old patients with atrial fibrillation may outweigh the bleeding risk. A sub-analysis of the IST-3 trial has shown for the first time that thrombolysis treatment in acute ischaemic stroke may be beneficial and safe even in octogenarian patients and older. Several recent observational studies have assessed thrombolysis in nonagenarians. The latest of these has shown better disability outcomes without increased rates of symptomatic intracerebral haemorrhage with thrombolysis.SummaryNonagenarian stroke patients may benefit from similar preventative and therapeutic strategies as their younger counterparts. A few important exceptions include primary prevention using aspirin or statins. Patient selection is nevertheless essential given the increased adverse event rates. Patient preference should play a key role in the decision-making process. Clinical trials including more nonagenarian patients are required to yield more robust evidence.

KW - stroke

KW - cerebrovascular disease

KW - Nonagenarian

KW - oldest old

KW - prevention

KW - management

KW - Prevention

KW - Stroke

KW - Oldest old

KW - Management

KW - Cerebrovascular disease

KW - LEFT ATRIAL APPENDAGE

KW - TISSUE-PLASMINOGEN ACTIVATOR

KW - CAROTID-ENDARTERECTOMY

KW - INDIVIDUAL PATIENT DATA

KW - HEALTH-CARE PROFESSIONALS

KW - ACUTE ISCHEMIC-STROKE

KW - DIRECT ORAL ANTICOAGULANTS

KW - CHRONIC KIDNEY-DISEASE

KW - ELDERLY-PATIENTS

KW - 80 YEARS OLD

UR - http://www.scopus.com/inward/record.url?scp=85065585335&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/prevention-treatment-acute-stroke-nonagenarians-beyond-medical-ethical-issues

U2 - 10.1007/s11940-019-0567-0

DO - 10.1007/s11940-019-0567-0

M3 - Article

VL - 21

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1534-3138

IS - 6

M1 - 27

ER -